ATRIAL FIBRILLATION IN PATIENTS OF CERTAIN CLINICAL GROUPS: FEATURES OF PATHOGENESIS AND IMPACT ON CATHETER ABLATION TACTICS

Highlights

In this review the authors have described the mechanism of atrial fibrillation (AF) development in patients with different comorbidity – in idiopathic AF, the AF concomitant to atrial hypertension and AF concomitant to ischemic heart disease. Currently, the treatment tactics for AF are based primarily on the duration of arrhythmia episodes, and not on the pathophysiological mechanisms of its development and progression. In our work, we tried to draw attention to the need for a pathogenetic view on the most common heart rhythm disease.

Abstract

The likelihood of atrial fibrillation occurrence increases with age and largely depends on the severity of concomitant cardiac and extracardiac pathology. In this review, we want to present an analysis of the data available in the literature on the pathogenesis and catheter treatment of atrial fibrillation in patients without visible structural and cardiovascular pathology (idiopathic atrial fibrillation), patients with hypertension and patients with coronary heart disease.

1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., Boriani G., Castella M., Dan G.A., Dilaveris P.E., et al. Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. .

2. Potpara T.S., Stankovic G.R., Beleslin B.D., Polovina M.M., Marinkovic J.M., Ostojic M.C., Lip G.Y.H. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation. Implications of arrhythmia progression on prognosis: The Belgrade atrial fibrillation study. Chest. 2012;141(2):339–47. doi: 10.1378/chest.11-0340.

3. Chiang C.E., Naditch-Brûlé L., Murin J., Goethals M., Inoue H., O-Neill J., Silva-Cardoso J., Zharinov O., Gamra H., Alam S., Ponikowski P., Lewalter T., Rosenqvist M., Steg P.G. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythmia Electrophysiol. 2012;5(4):632–9. doi: 10.1161/CIRCEP.112.970749.

4. Wyse D.G., Van Gelder I.C., Ellinor P.T., Go A.S., Kalman J.M., Narayan S.M., Nattel S., Schotten U., Rienstra M. Lone atrial fibrillation: Does it exist? J Am Coll Cardiol. 2014;63(17):1715–23. doi: 10.1016/j.jacc.2014.01.023.

5. Wyse D.G., Van Gelder I.C., Ellinor P.T., Go A.S., Kalman J.M., Narayan S.M., Nattel S., Schotten U., Rienstra M. Lone atrial fibrillation: Does it exist? J Am Coll Cardiol. 2014;63(17):1715–23. doi: 10.1016/j.jacc.2014.01.023.

6. Haïssaguerre M., Jaïs P., Shah D.C., Takahashi .A., Hocini M., Quiniou G., Garrigue S., Le Mouroux A., Le Métayer P., Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–66. doi: 10.1056/NEJM199809033391003.

7. Scherlag B.J., Nakagawa H., Jackman W.M., Yamanashi W.S., Patterson E., Po S., Lazzara R. Electrical stimulation to identify neural elements on the heart: Their role in atrial fibrillation. J Interv Card Electrophysiol. 2005;13(SUPPL. 1):37–42. doi: 10.1007/s10840-005-2492-2.

8. Zimmermann M., Adamec R., Metzger J. Atrial vulnerability in patients with paroxysmal “lone” atrial fibrillation. PACE - Pacing Clin Electrophysiol. 1998;21(10):1949–58. doi: 10.1111/j.1540-8159.1998.tb00015.x.

9. Teh A.W., Kistler P.M., Lee G., Medi C., Heck P.M., Spence S.J., Morton J.B., Sanders P., Kalman J.M. Long-term effects of catheter ablation for lone atrial fibrillation: Progressive atrial electroanatomic substrate remodeling despite successful ablation. Hear Rhythm. 2012;9(4):473–80. doi: 10.1016/j.hrthm.2011.11.013.

10. Husser D., Ueberham L., Hindricks G., Büttner P., Ingram C., Weeke P., Shoemaker M.B., Adams V., Arya A., Sommer P., Darbar D., Roden D.M., Bollmann A. Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation. PLoS One. 2017;12(8):e0183690. doi: 10.1371/journal.pone.0183690.

11. Batalov R.E., Khlynin M.S., Rogovskaya Y.V., Sazonova S.I., Tatarskiy R.B., Anfinogenova N.D., Popov S.V. Isolated Atrial Fibrillation, Inflammation and Efficacy of Radiofrequency Ablation: Preliminary Insights Based on a Single-Center Endomyocardial Biopsy Study. J Clin Med. 2023;12(4):1254. doi: 10.3390/jcm12041254.

12. Fredersdorf S., Ücer E., Jungbauer C., Dornia C., Eglmeier J., Eissnert C., Hamer O.W., Weber S., Arzt M., von Bary C. Lone atrial fibrillation as a positive predictor of left atrial volume reduction following ablation of atrial fibrillation. Europace. 2014;16(1):26–32. doi: 10.1093/europace/eut152.

13. Ilyushenkova J., Sazonova S., Popov E., Zavadovsky K., Batalov R., Archakov E., Moskovskih T., Popov S., Minin S., Romanov A. Radiomic phenotype of epicardial adipose tissue in the prognosis of atrial fibrillation recurrence after catheter ablation in patients with lone atrial fibrillation. J Arrhythmia. 2022;38(5):682–93. doi: 10.1002/joa3.12760.

14. Ilyushenkova J.N., Sazonova S.I., Popov E.V., Batalov R.E., Minin S.M., Romanov A.B. Radiomic Phenotype of Periatrial Adipose Tissue in the Prognosis of Late Postablation Recurrence of Idiopathic Atrial Fibrillation. Sovremennye tehnologii v medicine. 2023;15(2):48–58. doi: 10.17691/stm2023.15.2.05.

15. Ferreira M., Laranjo S., Cunha P., Geraldes V., Oliveira M., Rocha I. Orthostatic Stress and Baroreflex Sensitivity: A Window into Autonomic Dysfunction in Lone Paroxysmal Atrial Fibrillation. J Clin Med. 2023;12(18):5857. doi: 10.3390/jcm12185857.

16. Efremidis M., Letsas K.P., Lioni L., Deftereos S., Giannopoulos G., Kossyvakis C., Tsikrikas S., Charalampous C., Kollias G., Xydonas S., Synetos A., Sideris A., Toutouzas K., Stefanadis C. The impact of vagotonic, adrenergic, and random type of paroxysmal atrial fibrillation on left atrial ablation outcomes. Int J Cardiol. 2013;168(4):4015–8. doi: 10.1016/j.ijcard.2013.06.075.

17. Zhou Q., Cao H., Xu Z., Lan R., Chen X., Wang D., Xu W. Baseline serum globulin as a predictor of the recurrence of lone atrial fibrillation after radiofrequency catheter ablation. Anatol J Cardiol. 2017;17(5):381–5. doi: 10.14744/AnatolJCardiol.2016.7393.

18. Cao H., Xu W., Chen X., Zhou Q., Lan R., Chen Y., Wang D. Functional promoter −1816C>G variant of RANKL predicts risk and prognosis of lone atrial fibrillation. Heart Vessels. 2019;34(1):151–8. doi: 10.1007/s00380-018-1222-5.

19. Li N., Feng Q., Yu F., Zhou J., Guo X. Plasma growth differentiation factor-15 in patients with “lone” atrial fibrillation. J Clin Lab Anal. 2022;36(5):1–7. doi: 10.1002/jcla.24373.

20. Shen Y, Ma G, Sun M, Li M, Chen M. Low plasma renin activity is associated with “Apparently” idiopathic atrial fibrillation. IJC Hear Vasc. 2023;49:101286. doi: 10.1016/j.ijcha.2023.101286.

21. Galenko O., Jacobs V., Knight S., Taylor M., Cutler M.J., Muhlestein J.B., Carlquist J.L., Knowlton K.U., Jared Bunch T. The role of microRNAs in the development, regulation, and treatment of atrial fibrillation. J Interv Card Electrophysiol. 2019;55(3):297–305. doi: 10.1007/s10840-018-0495-z.

22. Canpolat U., Aytemir K., Hazirolan T., Özer N., Oto A. Relationship between vitamin D level and left atrial fibrosis in patients with lone paroxysmal atrial fibrillation undergoing cryoballoon-based catheter ablation. J Cardiol. 2017;69(1):16–23. doi: 10.1016/j.jjcc.2016.06.012.

23. Wijesurendra R.S., Liu A., Eichhorn C., Ariga R., Levelt E., Clarke W.T., Rodgers C.T., Karamitsos T.D., Bashir Y., Ginks M., Rajappan K., Betts T., Ferreira V.M., Neubauer S., Casadei B. Lone Atrial Fibrillation Is Associated With Impaired Left Ventricular Energetics That Persists Despite Successful Catheter Ablation. Circulation. 2016;134(15):1068-1081. doi: 10.1161/CIRCULATIONAHA.116.022931.

24. Mironova E.S., Mironov N.Y., Mironova N.A., Novikov P.S., Novikov I.A., Layovich L.Y., Maykov E.B., Golitsyn S.P. Electrophysiological cardiac parameters and results of antiarrhythmic treatment in patients with paroxysmal atrial fibrillation (lone and associated with arterial hypertension). Kardiologiya. 2019;59(8):39–46. doi: 10.18087/cardio.2019.8.n644. (In Russian)

25. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, Incidence, Prognosis, and Predisposing Conditions for Atrial Fibrillation: Population-Based Estimates. Am J Cardiol. 1998;82(7 A):2N-9N. doi: 10.1016/s0002-9149(98)00583-9.

26. Dzeshka M.S., Shantsila A., Shantsila E., Lip G.Y.H. Atrial Fibrillation and Hypertension. Hypertension. 2017;70(5):854–61. doi: 10.1161/HYPERTENSIONAHA.117.08934.

27. Gorenek B, Pelliccia A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, e Van Gelder IC, Halle M, Kudaiberdieva G, Lane DAt al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2017;19(2):190–225. doi: 10.1093/europace/euw242.

28. Allan V., Honarbakhsh S., Casas J.P., Wallace J., Hunter R., Schilling R., Perel P., Morley K., Banerjee A., Hemingway H. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation?: A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017;117(5):837–50. doi: 10.1160/TH16-11-0825.

29. Ikejder Y., Sebbani M., Hendy I., Khramz M., Khatouri A., Bendriss L. Impact of Arterial Hypertension on Left Atrial Size and Function. Biomed Res Int. 2020;2020:2587530. doi: 10.1155/2020/2587530.

30. Verdecchia P., Reboldi G.P., Gattobigio R., Bentivoglio M., Borgioni C., Angeli F., Carluccio E., Sardone M.G., Porcellati C.Atrial fibrillation in hypertension: Predictors and outcome. Hypertension. 2003;41(2):218–23. doi: 10.1161/01.hyp.0000052830.02773.e4.

31. Larstorp A.C.K., Stokke I.M., Kjeldsen S.E., Hecht Olsen M., Okin P.M., Devereux R.B., Wachtell K. Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. Blood Press. 2019;28(5):317–26. doi: 10.1080/08037051.2019.1633905.

32. Okin P.M., Hille D.A., Larstorp A.C.K., Wachtell K., Kjeldsen S.E., Dahlöf B., Devereux R.B. Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients. Hypertension. 2015;66(2):368–73. doi: 10.1161/HYPERTENSIONAHA.115.05728.

33. Galzerano D., Di Michele S., Paolisso G., Tuccillo B., Lama D., Carbotta S., Cittadini A., Tedesco M.A., Gaudio C. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. JRAAS - J Renin-Angiotensin-Aldosterone Syst. 2012;13(4):496–503. doi: 10.1177/1470320312443909.

34. Zhao Z., Yang Y., Wang J., Dong Z., Niu X., Liu E., Liu T., Li L., Liang Y., Li G. Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial. Clin Cardiol. 2020;43(12):1592–600. doi: 10.1002/clc.23487.

35. Okin P.M., Wachtell K., Kjeldsen S.E., Julius S., Lindholm L.H., Dahlöf B., Hille D.A., Nieminen M.S., Edelman J.M., Devereux R.B. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol. 2008;1(5):337–43. doi: 10.1161/CIRCEP.108.795351.

36. Steinberg J.S., Blount N., Ponomarev D., Shabanov V., Pokushalov E., Romanov A. The Evaluate Renal Artery Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF) trial: arrhythmia suppression, blood pressure control, and potential interactions. Europace. 2023;25(5): euad107. doi: 10.1093/europace/euad107.

37. Giannopoulos G., Kossyvakis C., Efremidis M., Katsivas A., Panagopoulou V., Doudoumis K., Raisakis K., Letsas K., Rentoukas I., Pyrgakis V., Manolis A.S., Tousoulis D., Stefanadis C., Deftereos S. Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: A randomized, controlled study. Circulation. 2014;130(16):1346–52. doi: 10.1161/CIRCULATIONAHA.114.010999.

38. Giannopoulos G., Kossyvakis C., Angelidis C., Efremidis M., Panagopoulou V., Letsas K., Bouras G., Vassilikos V.P., Goudevenos J., Tousoulis D., Lekakis J., Deftereos S. Amino-terminal B-natriuretic peptide levels and postablation recurrence in hypertensive patients with paroxysmal atrial fibrillation. Hear Rhythm [Internet]. 2015;12(7):1470–5. doi: 10.1016/j.hrthm.2015.04.002.

39. Winkle R.A., Jarman J.W.E., Mead R.H., Engel G., Kong M.H., Fleming W., Patrawala R.A. Predicting atrial fibrillation ablation outcome: The CAAP-AF score. Hear Rhythm. 2016;13(11):2119–25. doi: 10.1016/j.hrthm.2016.07.018.

40. Michniewicz E., Mlodawska E., Lopatowska P., Tomaszuk-Kazberuk A., Malyszko J. Patients with atrial fibrillation and coronary artery disease – Double trouble. Adv Med Sci. 2018;63(1):30–5. doi: 10.1016/j.advms.2017.06.005.

41. Bayrakova Yu.V., Ponasenko A.V., Khutornaya M. V., Kuzmina A.A., Kazachek Yu.V., Barbarash O.L. The role of polymorphisms of crp gene in occurrence of atrial fibrilation in cad patients. Complex Issues Cardiovasc Dis [Internet]. 2017 Jan 1;(3):37–46. doi:10.17802/2306-1278-2017-6-3-37-46 (In Russian)

42. Kornej J., Hindricks G., Arya A., Sommer P., Husser D., Rolf S., Bollmann A. Presence and extent of coronary artery disease as predictor for AF recurrences after catheter ablation: The Leipzig Heart Center AF Ablation Registry. Int J Cardiol. 2015;181:188–92. doi: 10.1016/j.ijcard.2014.12.039.

43. Liu L., Zhao D., Zhang J., Yang H., Abdu F.A., Guo R., Li S., Tang K., Li H., Che W., Xu Y. Impact of Stable Coronary Artery Disease on the Efficacy of Cryoballoon Ablation for the Atrial Fibrillation. Am J Med Sci]. 2019;358(3):204–11. doi: 10.1016/j.amjms.2019.06.004.

44. Winkle R.A., Mead R.H., Engel G., Patrawala R.A. Long-term results of atrial fibrillation ablation: The importance of all initial ablation failures undergoing a repeat ablation. Am Heart J. 2011;162(1):193–200. doi: 10.1016/j.ahj.2011.04.013.

45. Marrouche N.F., Wilber D., Hindricks G., Jais P., Akoum N., Marchlinski F., Kholmovski E., Burgon N., Hu N., Mont L. et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF study. JAMA - J Am Med Assoc. 2014;311(5):498–506. doi: 10.1001/jama.2014.3.

46. Oakes R.S., Badger T.J., Kholmovski E.G., Akoum N., Burgon N.S., Fish E.N., Blauer J.J., Rao S.N., DiBella E.V., Segerson N.M., Daccarett M., Windfelder J., McGann C.J., Parker D., MacLeod R.S., Marrouche N.F. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009;119(13):1758–67. doi: 10.1161/CIRCULATIONAHA.108.811877.

47. Hiraya D., Sato A., Hoshi T., Watabe H., Yoshida K., Komatsu Y., Sekiguchi Y., Nogami A., Ieda M., Aonuma K.. Impact of coronary artery disease and revascularization on recurrence of atrial fibrillation after catheter ablation: Importance of ischemia in managing atrial fibrillation. J Cardiovasc Electrophysiol. 2019;30(9):1491–8. doi: 10.1111/jce.14029.

48. Packer D.L., Mark D.B., Robb R.A., Monahan K.H., Bahnson T.D., Poole J.E., Noseworthy P.A., Rosenberg Y.D., Jeffries N., Mitchell L.B. et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest among Patients with Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA - J Am Med Assoc. 2019;321(13):1261–74. doi: 10.1001/jama.2019.0693.

49. Arakelyan M.G., Bockeria L.A., Vasilieva E.Y., Golitsyn S.P., Golukhova E.Z., Gorev M.V., Davtyan K.V., Drapkina O.M., Kropacheva E.S., Kuchinskaya E.A. et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russ J Cardiol. 20218;26(7):4594. doi:10.15829/1560-4071-2021-4594 (In Russian)

50. Verma A., Jiang C., Betts T.R., Chen J., Deisenhofer I., Mantovan R., Macle L., Morillo C.A., Haverkamp W., Weerasooriya R., Albenque J.P., Nardi S., Menardi E., Novak P., Sanders P.; STAR AF II Investigators. Approaches to Catheter Ablation for Persistent Atrial Fibrillation. N Engl J Med. 2015;372(19):1812–22.

51. Balaji S., Kron J., Stecker E.C. Catheter Ablation of Recurrent Lone Atrial Fibrillation in Teenagers with a Structurally Normal Heart. Pacing Clin Electrophysiol. 2016;39(1):60–4. doi: 10.1111/pace.12774.

52. Parlavecchio A., Vetta G., Coluccia G., Pistelli L., Caminiti R., Ajello M., Magnocavallo M., Dattilo G., Foti R., Carerj S., Crea P., Accogli M., Chierchia G.B., de Asmundis C., Della Rocca D.G., Palmisano P. Catheter ablation in patients with paroxysmal atrial fibrillation and absence of structural heart disease: A meta-analysis of randomized trials. IJC Hear Vasc. 2023;49:101292. doi: 10.1016/j.ijcha.2023.101292.

53. Furst M.L., Saarel E.V., Hussein A.A., Wazni .O.M., Tchou P., Kanj M., Saliba W.I., Aziz P.F. Medical and Interventional Outcomes in Pediatric Lone Atrial Fibrillation. JACC Clin Electrophysiol. 2018;4(5):638–48. doi: 10.1016/j.jacep.2018.02.014.

54. El Assaad I., Hammond B.H., Kost L.D., Worley S., Janson C.M., Sherwin E.D., Stephenson E.A., Johnsrude C.L., Niu M., Shetty I., Lawrence D., McCanta A.C., Balaji S., Sanatani S., Fish F., Webster G., Aziz P.F. Management and outcomes of atrial fibrillation in 241 healthy children and young adults: Revisiting “lone” atrial fibrillation—A multi-institutional PACES collaborative study. Hear Rhythm. 2021;18(11):1815–22. doi: 10.1016/j.hrthm.2021.07.066.

55. Khidirova L.D., Yakhontov D.A., Zenin S.A. Atrial fibrillation in comorbid patients depending on the treatment regimen. Complex Issues of Cardiovascular Diseases. 2019;8(2):21–9. doi:10.17802/2306-1278-2019-8-2-21-29 (In Russian)

56. Pison L., Hocini M., Potpara T.S., Todd D., Chen J., Blomstrom-Lundqvist C.; Scientific Initiative Committee, European Heart Rhythm Association. Work-up and management of lone atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace. 2014;16(10):1521–3. doi: 10.1093/europace/euu277.

57. Aryana A., Baker J.H., Espinosa Ginic M.A., Pujara D.K., Bowers M.R., O’Neill P.G., Ellenbogen K.A., Di Biase L., d'Avila A., Natale A. Posterior wall isolation using the cryoballoon in conjunction with pulmonary vein ablation is superior to pulmonary vein isolation alone in patients with persistent atrial fibrillation: A multicenter experience. Hear Rhythm. 2018;15(8):1121–9. doi: 10.1016/j.hrthm.2018.05.014.

58. Buiatti A., Kaess B., Reents T., Semmler V., Telishveska M., Bourier F., Kornmayer M., Kottmaier M., Hessling G., Deisenhofer I. Catheter Ablation for “Lone” Atrial Fibrillation: Efficacy and Predictors of Recurrence. J Cardiovasc Electrophysiol. 2016;27(5):536–41. doi: 10.1111/jce.12936.

59. Gorev M.V., Urazovskaya I.L., Sayganov S.A. Intraoperative atrial rhythm changes during atrial fibrillation catheter ablation in patients with arterial hypertension and coronary artery disease. Sib J Clin Exp Med. 2024;38(4):167–75. A doi:10.29001/2073-8552-2023-38-4-167-175 (In Russian)

60. Sato T., Sotomi Y., Hikoso S., Nakatani D., Mizuno H., Okada K., Dohi T., Kitamura T., Sunaga A., Kida H. et al. DR-FLASH Score Is Useful for Identifying Patients With Persistent Atrial Fibrillation Who Require Extensive Catheter Ablation Procedures. J Am Heart Assoc. 2022;11(16). doi: 10.1161/JAHA.121.024916.

61. Chen J., Wang H., Zhou M., Zhao L. Catheter ablation for lone atrial fibrillation in individuals aged under 35 years. 2019; 29(5):643-648. doi: 10.1017/S1047951119000416.

62. Pison L., Gelsomino S., Lucà F., Parise O., Maessen J.G., Crijns H.J., La Meir M. Effectiveness and safety of simultaneous hybrid thoracoscopic and endocardial catheter ablation of lone atrial fibrillation. 2014;3(1):38–44. doi: 10.3978/j.issn.2225-319X.2013.12.10.

63. Qin M., Liu X., Jiang W., Wu S., Zhang X., Po S. Vagal response during pulmonary vein isolation: Re-recognized its characteristics and implications in lone paroxysmal atrial fibrillation. Int J Cardiol. 2016;211:7–13. doi: 10.1016/j.ijcard.2016.02.116.

64. Steinberg J.S., Shabanov V., Ponomarev D., Losik D., Ivanickiy E., Kropotkin E., Polyakov K., Ptaszynski P., Keweloh B., Yao C.J., Pokushalov E.A., Romanov A.B. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence among Patients with Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA - J Am Med Assoc. 2020;323(3):248–55. doi: 10.1001/jama.2019.21187.

65. Heradien M., Mahfoud F., Greyling C., Lauder L., van der Bijl P., Hettrick D.A., Stilwaney W., Sibeko S., Jansen van Rensburg R., Peterson D., Khwinani B., Goosen A., Saaiman J.A., Ukena C., Böhm M., Brink P.A. Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: Randomized, sham-controlled trial. Hear Rhythm. 2022;19(11):1765–73. doi: 10.1016/j.hrthm.2022.06.031.

66. Kiuchi M.G., Chen S., Hoye N.A., Pürerfellner H. Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. J Interv Card Electrophysiol. 2018;51(1):51–9. doi: 10.1007/s10840-017-0302-2.

67. Kirstein B., Tomala J., Mayer J., Ulbrich S., Wagner M., Pu L., Piorkowski J., Hankel A., Huo Y.,Gaspar T., Richter U., Hindricks G., Piorkowski C. Effect of concomitant Renal DeNervation and cardiac ablation on Atrial Fibrillation recurrence – RDN+AF study. J Cardiovasc Electrophysiol. 2023;34(1):44–53. doi: 10.1111/jce.15714.